Increased perioperative mortality following aprotinin withdrawal: A real-world analysis of blood management strategies in adult cardiac surgery

Intensive Care Medicine

Volumn 39, Issue 10, 2013, Pages 1808-1817

  Walkden, Graham J ^a   Verheyden, Veerle ^b,c   Goudie, Rosalind ^a   Murphy, Gavin J ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Aprotinin; Blood management; Cardiac surgery; Mortality

Indexed keywords

APROTININ; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLOOD CONSERVATION; CARDIOGENIC SHOCK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FEMALE; FORWARD HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SURGERY; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION COMPLICATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; STERNOTOMY; SURGICAL MORTALITY; TERTIARY HEALTH CARE; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; APROTININ; BLOOD COAGULATION FACTORS; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CASE-CONTROL STUDIES; ENGLAND; FEMALE; HEMORRHAGE; HEMOSTATICS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAFETY-BASED DRUG WITHDRAWALS; TIME FACTORS;

EID: 84884596241     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-013-3020-y     Document Type: Article

References (34)

1. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J (2004) The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44:1453-1462
2. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone EH (2006) Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 34:1608-1616
3. Unsworth-White MJ, Herriot A, Valencia O, Poloniecki J, Smith EE, Murday AJ, Parker DJ, Treasure T (1995) Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 59:664-667
4. UK Transfusion audit. Bridgewater B, Keogh B Demonstrating Quality: The Society of Cardiothoracic Surgeons of Great Britain and Ireland National Sixth Adult Cardiac Surgical Database Report 2008. Dendrite Clinical Systems, Oxfordshire
5. Bridgewater B, Keogh B Demonstrating Quality: The Society of Cardiothoracic Surgeons of Great Britain and Ireland National Sixth Adult Cardiac Surgical Database Report 2008. Dendrite Clinical Systems, Oxforshire
6. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, Fitzgerald DJ, Likosky DS, Shann KG (2011) 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91:944-982
7. Ranucci M, Aronson S, Dietrich W, Dyke CM, Hofmann A, Karkouti K, Levi M, Murphy GJ, Sellke F, Shore-Lesserson L, von Heymann C (2011) Patient blood management during cardiac surgery: do we have enough evidence for clinical practice? J Thorac Cardiovasc Surg 142:249.e1-249.e32
8. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 16:CD001886
9. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation (2006) The risk associated with aprotinin in cardiac surgery. N Engl J Med 354:353-365
10. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF (2008) The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358:784-793
11. Schneeweiss S, Seeger JD, Landon J, Walker AM (2008) Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358:771-783
12. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM et al (2008) A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358:2319-2331
13. Beattie WS, Karkouti K (2011) The post-BART anti-fibrinolytic dilemma. J Cardiothorac Vasc Anesth 25:3-5
14. Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R (2010) Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. doi: 10.1007/s00134-010-1991-5
15. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55
16. Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33-38
17. Ichino A, Mealli F, Mannicini T (2008) From temporary help jobs to permanent employment: what can we learn from matching estimators and their sensitivity? J Appl Econom 23:203-227
18. Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A (2012) Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. BMJ 345:e5798
19. Howell N, Senanayake E, Freemantle N, Pagano D (1013) Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 145:234-240
20. Brown JR, Birkmeyer NJ, O'Connor GT (2007) Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115:2801-2813
21. Gagne JJ, Griesdale DE, Schneeweiss S (2009) Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf 18:259-268
22. Meybohm P, Herrmann E, Nierhoff J, Zacharowski K (2013) Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and epsilon-aminocaproic acid - a meta-analysis of randomised and observational trials over 30,000 patients. PLoS ONE. doi: 10.1371/journal.pone.0058009
23. Pagano D, Howell NJ, Freemantle N, Cunningham D, Bonser RS, Graham TR, Mascaro J, Rooney SJ, Wilson IC, Cramb R, Keogh BE (2008) Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 135:495-502
24. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Hu S (2010) Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. Ann Thorac Surg 89:1489-1495
25. Dietrich W, Busley R, Boulesteix AL (2008) Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin. Anesthesiology 108:189-198
26. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS (2010) The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 110:21-29
27. Ngaage DL, Cale AR, Cowen ME, Griffin S, Guvendik L (2008) Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann Thorac Surg 86:1195-1202
28. Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page US 3rd (2007) Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116:127-133
29. Bryan AJ, Cohen AM, Davies A. Bristol Heart Institute Cardiac Services Adult Cardiac Surgery Activity Report 2009-10. Available via http://www.uhbristol.nhs.uk/media/1467094/acsar09-10-ad-2-feb-2012.pdf. Accessed 1st Jul 2013
30. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C (2010) Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 14:R148
31. Strouch ZY, Drum ML, Chaney MA (2009) Aprotinin use during cardiac surgery: recent alterations and effects on blood product utilization. J Clin Anesth 21:502-507
32. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Li L, Hu S (2009) A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg 138:897-903
33. Sniecinski RM, Chen EP, Makadia SS, Kikura M, Bolliger D, Tanaka KA (2010) Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 24:959-963
34. Martin K, Wiesner G, Breuer T, Lange R, Tassani P (2008) The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 107:1783-1790